Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis.

What was studied

This review pooled bleeding events in people with hemophilia B. Hemophilia B is a rare condition with lacking one clotting factor. The people had no inhibitors and got preventive clotting factor replacement. The search found 5684 citations, and 24 trials and 53 observational studies were pooled. The team looked at annual bleeding rate, joint bleeds, spontaneous bleeds and bleeds from injury.

What they found

In 13 trials, the treated annual bleeding rate (ABR) was 2.23. In 22 trials, the treated or unspecified ABR was 2.25. In 48 observational studies, it was 2.08. ABR was generally lower under age 12 than at age 12 or more. It was also generally lower with extended products than with standard ones.

What it means for patients

The authors say these results reflect advances in hemophilia B care. They also point to unmet needs. Many people still have repeated bleeding events each year.

Why it is not certain yet

ABR definitions varied across studies. Follow-up times also varied. These may add differences into the pooled estimates. Results combine trials and observational studies.

Source

Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.